Profile - To The Moon

JB0112

Stock Noob

Posts · 77Posts · 77
Following · 0Following · 0
Followers · 0Followers · 0

- JB0112JB0112
  ·2023-06-13
  $Invitae(NVTA)$
  1.82K Comment
  1
  Share
  Report
- JB0112JB0112
  ·2022-09-09
  $Bed Bath & Beyond(BBBY)$CCome on!
  1.57K Comment
  Like
  Share
  Report
- JB0112JB0112
  ·2022-09-09
  $Invitae(NVTA)$
  1.70K Comment
  1
  Share
  Report
- JB0112JB0112
  ·2022-09-09
  Great
  Sorry, this post has been deleted
  2.01K 2
  2
  Share
  Report
- JB0112JB0112
  ·2022-08-27
  $JD.com(JD)$
  2.18K Comment
  Like
  Share
  Report
- JB0112JB0112
  ·2022-08-27
  $Agora, Inc.(API)$[Happy]
  1.91K Comment
  Like
  Share
  Report
- JB0112JB0112
  ·2022-01-08
  buy
  Here's Why Roku Stock Is Already Down 15% in 2022
  Could the stock fall 50% more than it already has?
  Here's Why Roku Stock Is Already Down 15% in 2022
  1.85K Comment
  2
  Share
  Report
- JB0112JB0112
  ·2022-01-07
  Go
  Absci Soared 48% in Premarket Trading as It Announced Research Collaboration with Merck
  Absci soared 48% in premarket trading as it announced research collaboration with Merck.Absci Corpor
  Absci Soared 48% in Premarket Trading as It Announced Research Collaboration with Merck
  1.61K Comment
  3
  Share
  Report
- JB0112JB0112
  ·2021-09-09
  $OncoSec Medical(ONCS)$Coin
  2.36K Comment
  1
  Share
  Report
- JB0112JB0112
  ·2021-09-01
  $OncoSec Medical(ONCS)$Further?
  2.12K Comment
  1
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3585877031221506","uuid":"3585877031221506","gmtCreate":1622783080026,"gmtModify":1661570220272,"name":"JB0112","pinyin":"jb0112","introduction":"","introductionEn":"","signature":"Stock Noob","avatar":"https://community-static.tradeup.com/news/cae997c1c9a68d587683bdf507166f18","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":12,"tweetSize":77,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.16","exceedPercentage":"93.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.13","exceedPercentage":"80.73%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.16","exceedPercentage":"93.56%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":8,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":186894790631552,"gmtCreate":1686667893519,"gmtModify":1686667896771,"author":{"id":"3585877031221506","authorId":"3585877031221506","name":"JB0112","avatar":"https://community-static.tradeup.com/news/cae997c1c9a68d587683bdf507166f18","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585877031221506","authorIdStr":"3585877031221506"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVTA\">$Invitae(NVTA)$ &nbsp;</a>","listText":"<a href=\"https://ttm.financial/S/NVTA\">$Invitae(NVTA)$ &nbsp;</a>","text":"$Invitae(NVTA)$","images":[{"img":"https://community-static.tradeup.com/news/3bb6854b4e3d8e6e1abfc950510ec5af","width":"882","height":"1608"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/186894790631552","isVote":1,"tweetType":1,"viewCount":1818,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9936115172,"gmtCreate":1662725869996,"gmtModify":1676537127732,"author":{"id":"3585877031221506","authorId":"3585877031221506","name":"JB0112","avatar":"https://community-static.tradeup.com/news/cae997c1c9a68d587683bdf507166f18","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585877031221506","authorIdStr":"3585877031221506"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/BBBY\">$Bed Bath &amp; Beyond(BBBY)$</a>CCome on!","listText":"<a href=\"https://ttm.financial/S/BBBY\">$Bed Bath &amp; Beyond(BBBY)$</a>CCome on!","text":"$Bed Bath & Beyond(BBBY)$CCome on!","images":[{"img":"https://community-static.tradeup.com/news/a9ca63d4921fe966b4aea7e612fd8842","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9936115172","isVote":1,"tweetType":1,"viewCount":1570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9936115944,"gmtCreate":1662725818088,"gmtModify":1676537127708,"author":{"id":"3585877031221506","authorId":"3585877031221506","name":"JB0112","avatar":"https://community-static.tradeup.com/news/cae997c1c9a68d587683bdf507166f18","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585877031221506","authorIdStr":"3585877031221506"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NVTA\">$Invitae(NVTA)$</a>","listText":"<a href=\"https://ttm.financial/S/NVTA\">$Invitae(NVTA)$</a>","text":"$Invitae(NVTA)$","images":[{"img":"https://community-static.tradeup.com/news/f89c58170b08a733d7f10389f9b4c20d","width":"1080","height":"1980"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9936115944","isVote":1,"tweetType":1,"viewCount":1697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9936112488,"gmtCreate":1662725747645,"gmtModify":1676537127700,"author":{"id":"3585877031221506","authorId":"3585877031221506","name":"JB0112","avatar":"https://community-static.tradeup.com/news/cae997c1c9a68d587683bdf507166f18","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585877031221506","authorIdStr":"3585877031221506"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9936112488","repostId":"1120245102","repostType":4,"isVote":1,"tweetType":1,"viewCount":2008,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9994851742,"gmtCreate":1661606855188,"gmtModify":1676536548919,"author":{"id":"3585877031221506","authorId":"3585877031221506","name":"JB0112","avatar":"https://community-static.tradeup.com/news/cae997c1c9a68d587683bdf507166f18","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585877031221506","authorIdStr":"3585877031221506"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/JD\">$JD.com(JD)$</a>","listText":"<a href=\"https://ttm.financial/S/JD\">$JD.com(JD)$</a>","text":"$JD.com(JD)$","images":[{"img":"https://community-static.tradeup.com/news/8edfc862f46521a5086204d8359b1bfd","width":"1080","height":"1980"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9994851742","isVote":1,"tweetType":1,"viewCount":2175,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9994310751,"gmtCreate":1661564105775,"gmtModify":1676536542006,"author":{"id":"3585877031221506","authorId":"3585877031221506","name":"JB0112","avatar":"https://community-static.tradeup.com/news/cae997c1c9a68d587683bdf507166f18","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585877031221506","authorIdStr":"3585877031221506"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/API\">$Agora, Inc.(API)$</a>[Happy]&nbsp;","listText":"<a href=\"https://ttm.financial/S/API\">$Agora, Inc.(API)$</a>[Happy]&nbsp;","text":"$Agora, Inc.(API)$[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9994310751","isVote":1,"tweetType":1,"viewCount":1914,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006192723,"gmtCreate":1641628185750,"gmtModify":1676533636060,"author":{"id":"3585877031221506","authorId":"3585877031221506","name":"JB0112","avatar":"https://community-static.tradeup.com/news/cae997c1c9a68d587683bdf507166f18","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585877031221506","authorIdStr":"3585877031221506"},"themes":[],"htmlText":"buy","listText":"buy","text":"buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006192723","repostId":"2201214400","repostType":2,"repost":{"id":"2201214400","kind":"highlight","pubTimestamp":1641567477,"share":"https://ttm.financial/m/news/2201214400?lang=&edition=fundamental","pubTime":"2022-01-07 22:57","market":"us","language":"en","title":"Here's Why Roku Stock Is Already Down 15% in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2201214400","media":"Motley Fool","summary":"Could the stock fall 50% more than it already has?","content":"<div>\n<p>What happenedIs Roku (NASDAQ:ROKU) stock grossly overvalued? That's a question a lot of investors are asking. And one Wall Street analyst just suggested this stock has roughly 50% more downside, which...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/heres-why-roku-stock-is-already-down-15-in-2022/\">Web Link</a>\n\n</div>\n","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why Roku Stock Is Already Down 15% in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why Roku Stock Is Already Down 15% in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/07/heres-why-roku-stock-is-already-down-15-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happenedIs Roku (NASDAQ:ROKU) stock grossly overvalued? That's a question a lot of investors are asking. And one Wall Street analyst just suggested this stock has roughly 50% more downside, which...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/heres-why-roku-stock-is-already-down-15-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ROKU":"Roku Inc","BK4108":"电影和娱乐","BK4507":"流媒体概念","BK4548":"巴美列捷福持仓","BK4524":"宅经济概念","BK4532":"文艺复兴科技持仓"},"source_url":"https://www.fool.com/investing/2022/01/07/heres-why-roku-stock-is-already-down-15-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201214400","content_text":"What happenedIs Roku (NASDAQ:ROKU) stock grossly overvalued? That's a question a lot of investors are asking. And one Wall Street analyst just suggested this stock has roughly 50% more downside, which is saying something considering the stock is already down about 60% from its all-time high. This is partly why, as of the market's close on Thursday, Roku is down 15.1% for 2022.So whatAccording to The Fly, Atlantic Equities analyst Hamilton Faber started covering Roku stock earlier this year. Faber started his coverage by slapping a $136-per-share price target on Roku, a roughly 50% downside from where it was trading at the time. Faber believes Roku will struggle to attract TV manufacturer partners for its connected-TV operating system software. For this reason and more, Roku stock doesn't deserve its pricy price-to-sales (P/S) valuation of 10.5, Faber said.Now whatLet's talk about Roku's business. According to the company, it closed 2020 as the most widely adopted operating system for smart TVs in the U.S. with 38% share of new TVs sold. And in the third quarter of 2021, Roku's 56.4 million active accounts streamed 18 billion hours of content. Both the number of active accounts and the number of hours streamed were up year over year.It's worth monitoring how well Roku is attracting partners, as Faber suggests. But considering Roku is still executing well, I believe investors should give it the benefit of the doubt for now.Regarding valuation, if Roku stock fell 50% from here, it would trade at a P/S of roughly 5. Coincidentally, this is about what its valuation was when it went public in 2017. However, back then, Roku's business was more heavily skewed toward its low-profit-margin hardware business. These days, its high-margin software business is in the driver's seat, boosting the company's overall profitability.Roku's gross margin for the first six months of 2017 was 38.2%. In the third quarter of 2021, it was 53.5%. Because its profitability has improved, assessing its current valuation and its past valuation isn't an apples-to-apples comparison -- higher-profit-margin companies generally have higher P/S valuations. For this reason, I think Roku's valuation is fair today, provided at can continue to gain new active accounts and increase its user monetization.","news_type":1,"symbols_score_info":{"ROKU":1}},"isVote":1,"tweetType":1,"viewCount":1852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006060616,"gmtCreate":1641555202245,"gmtModify":1676533628658,"author":{"id":"3585877031221506","authorId":"3585877031221506","name":"JB0112","avatar":"https://community-static.tradeup.com/news/cae997c1c9a68d587683bdf507166f18","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585877031221506","authorIdStr":"3585877031221506"},"themes":[],"htmlText":"Go","listText":"Go","text":"Go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006060616","repostId":"1182192803","repostType":2,"repost":{"id":"1182192803","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641553786,"share":"https://ttm.financial/m/news/1182192803?lang=&edition=fundamental","pubTime":"2022-01-07 19:09","market":"us","language":"en","title":"Absci Soared 48% in Premarket Trading as It Announced Research Collaboration with Merck","url":"https://stock-news.laohu8.com/highlight/detail?id=1182192803","media":"Tiger Newspress","summary":"Absci soared 48% in premarket trading as it announced research collaboration with Merck.Absci Corpor","content":"<html><head></head><body><p>Absci soared 48% in premarket trading as it announced research collaboration with Merck.<img src=\"https://static.tigerbbs.com/f40d09f65f69c4d2abcbbf62f0783f58\" tg-width=\"1126\" tg-height=\"761\" referrerpolicy=\"no-referrer\"/>Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that it has entered into a research collaboration with Merck (known as MSD outside the United States and Canada), using Absci’s AI-powered Integrated Drug Creation™ Platform.</p><p>Under the collaboration, Absci will deploy its Bionic Protein™ non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications and receive an upfront and certain other milestone payments. In addition, Merck has the option to nominate up to three targets and enter into a drug discovery collaboration agreement, and Absci would then be eligible to receive up to $610 million in upfront fees and milestone payments for all three targets, as well as research funding and tiered royalties on sales.</p><p>Sean McClain, founder and CEO of Absci, commented, “We are very pleased to establish this collaboration with Merck and to be working with its world class research organization to generate novel enzymes. We look forward to applying our AI-driven platform to create new biologic candidates with the potential to meaningfully improve the lives of patients.”</p><p>“At Merck we are continually evaluating new ways to build, expand and refine our biologics capabilities,” said Dr. Fiona Marshall, senior vice president and head of discovery, preclinical and translation medicine, Merck Research Laboratories. “Absci’s platform offers a compelling opportunity to design new biologic candidates and explore the expression of complex proteins.”</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Absci Soared 48% in Premarket Trading as It Announced Research Collaboration with Merck</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbsci Soared 48% in Premarket Trading as It Announced Research Collaboration with Merck\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-07 19:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Absci soared 48% in premarket trading as it announced research collaboration with Merck.<img src=\"https://static.tigerbbs.com/f40d09f65f69c4d2abcbbf62f0783f58\" tg-width=\"1126\" tg-height=\"761\" referrerpolicy=\"no-referrer\"/>Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that it has entered into a research collaboration with Merck (known as MSD outside the United States and Canada), using Absci’s AI-powered Integrated Drug Creation™ Platform.</p><p>Under the collaboration, Absci will deploy its Bionic Protein™ non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications and receive an upfront and certain other milestone payments. In addition, Merck has the option to nominate up to three targets and enter into a drug discovery collaboration agreement, and Absci would then be eligible to receive up to $610 million in upfront fees and milestone payments for all three targets, as well as research funding and tiered royalties on sales.</p><p>Sean McClain, founder and CEO of Absci, commented, “We are very pleased to establish this collaboration with Merck and to be working with its world class research organization to generate novel enzymes. We look forward to applying our AI-driven platform to create new biologic candidates with the potential to meaningfully improve the lives of patients.”</p><p>“At Merck we are continually evaluating new ways to build, expand and refine our biologics capabilities,” said Dr. Fiona Marshall, senior vice president and head of discovery, preclinical and translation medicine, Merck Research Laboratories. “Absci’s platform offers a compelling opportunity to design new biologic candidates and explore the expression of complex proteins.”</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","ABSI":"Absci Corporation."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182192803","content_text":"Absci soared 48% in premarket trading as it announced research collaboration with Merck.Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that it has entered into a research collaboration with Merck (known as MSD outside the United States and Canada), using Absci’s AI-powered Integrated Drug Creation™ Platform.Under the collaboration, Absci will deploy its Bionic Protein™ non-standard amino acid technology to produce enzymes tailored to Merck’s biomanufacturing applications and receive an upfront and certain other milestone payments. In addition, Merck has the option to nominate up to three targets and enter into a drug discovery collaboration agreement, and Absci would then be eligible to receive up to $610 million in upfront fees and milestone payments for all three targets, as well as research funding and tiered royalties on sales.Sean McClain, founder and CEO of Absci, commented, “We are very pleased to establish this collaboration with Merck and to be working with its world class research organization to generate novel enzymes. We look forward to applying our AI-driven platform to create new biologic candidates with the potential to meaningfully improve the lives of patients.”“At Merck we are continually evaluating new ways to build, expand and refine our biologics capabilities,” said Dr. Fiona Marshall, senior vice president and head of discovery, preclinical and translation medicine, Merck Research Laboratories. “Absci’s platform offers a compelling opportunity to design new biologic candidates and explore the expression of complex proteins.”","news_type":1,"symbols_score_info":{"MRK":0.9,"ABSI":0.9}},"isVote":1,"tweetType":1,"viewCount":1605,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889727650,"gmtCreate":1631181689370,"gmtModify":1676530489302,"author":{"id":"3585877031221506","authorId":"3585877031221506","name":"JB0112","avatar":"https://community-static.tradeup.com/news/cae997c1c9a68d587683bdf507166f18","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585877031221506","authorIdStr":"3585877031221506"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ONCS\">$OncoSec Medical(ONCS)$</a>Coin","listText":"<a href=\"https://laohu8.com/S/ONCS\">$OncoSec Medical(ONCS)$</a>Coin","text":"$OncoSec Medical(ONCS)$Coin","images":[{"img":"https://static.tigerbbs.com/2a8fc76b9b21f544a12e0996d1a39f14","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889727650","isVote":1,"tweetType":1,"viewCount":2358,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":816110244,"gmtCreate":1630476763588,"gmtModify":1676530314098,"author":{"id":"3585877031221506","authorId":"3585877031221506","name":"JB0112","avatar":"https://community-static.tradeup.com/news/cae997c1c9a68d587683bdf507166f18","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585877031221506","authorIdStr":"3585877031221506"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ONCS\">$OncoSec Medical(ONCS)$</a>Further?","listText":"<a href=\"https://laohu8.com/S/ONCS\">$OncoSec Medical(ONCS)$</a>Further?","text":"$OncoSec Medical(ONCS)$Further?","images":[{"img":"https://static.tigerbbs.com/008e5c7063c0b47135ba54daf80b462d","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/816110244","isVote":1,"tweetType":1,"viewCount":2117,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}